BETRF Stock — BetterLife Pharma Inc

BetterLife Pharma Inc (BETRF)

Updated October 16, 2026.

BETRF is a Stock. Total return is -97.7% over the past 15.7 years, 774.1 points behind SPY at 676.4%.

BetterLife Pharma is a biotechnology company developing psychedelic-derived compounds and other therapeutic treatments, including BETR-001, a non-hallucinogenic LSD derivative for neuro-psychiatric and neurological disorders, along with topical and inhalation-based products for other indications. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development rather than those focused on income.

BETRF performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.7% over the past 15.7 years, 774.1 points behind SPY at 676.4%. Over the past year its total return — price change plus distributions reinvested — is 308.2%. Its deepest 1-year drawdown was 46.9%.

BETRF key facts

Asset type

Stock

Asset class

Equity

Inception date

01/18/2011

Distribution frequency

None

Last close

$0.16 (as of 2026-10-16)

Market cap

$98,386,743

Average volume

34500.0

Payment date

06/26/2020

Beta

0.22

Payout ratio

0.0%

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BETRF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 46.9%.

Who may consider BETRF — and who may not

It is a weaker fit for investors who need monthly cash flow (BETRF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BETRF

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions